Pharmaceutical Technology
SEPTEMBER 21, 2022
The most advanced programme of the company is adeno-associated virus (AAV)-based gene therapy, REN-001. It leverages gene transfer technology to target the monogenic cause of BAG3-linked dilated cardiomyopathy (DCM), a severe kind of heart failure. .
Scienmag
JANUARY 28, 2021
— In a new study published in Circulation, Mayo Clinic researchers provide the first preclinical, proof-of-concept study for hybrid gene therapy in long QT syndrome, a potentially lethal heart rhythm condition. ROCHESTER, Minn.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT News
JANUARY 6, 2023
… Pfizer told employees it plans to pull back on early-stage research into treatments for rare diseases, including the development of new viral-based gene therapies , Barron’s reports. Among the assets on the chopping block is a gene therapy manufacturing facility in Durham, N.C.,
STAT News
JULY 12, 2022
The treatment is aimed at a relatively common form of high cholesterol that affects millions of people, a very different population than those normally treated with gene therapies. The company studying the treatment, Verve Therapeutics, announced the news Tuesday. Continue to STAT+ to read the full story…
The Pharma Data
FEBRUARY 21, 2022
Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.
Pharma Marketing Network
FEBRUARY 27, 2025
Scientific blogs discussing new advancements in oncology, cardiology, or rare diseases. For example, a LinkedIn article on the future of gene therapy can position a brand as an authority in genetic medicine, attracting biotech investors, researchers, and prescribing physicians.
Scienmag
MAY 17, 2021
Patients’ genetic profile strongly influences size of effect in early-phase trial People with extremely high levels of triglycerides (a type of fat in the blood) and a specific genetic profile saw a substantial reduction in triglycerides after taking the human monoclonal antibody evinacumab compared with those taking a placebo, in a study presented (..)
Expert insights. Personalized for you.
147 
Let's personalize your content